Phosphoinositide- phospholipase C β1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia

Journal of Clinical Oncology

Volumn 27, Issue 5, 2009, Pages 782-790

  Folio, Matilde Y ^a   Finelli, Carlo ^a   Clissa, Cristina ^a   Mongiorgi, Sara ^a   Bosi, Costanza ^a   Martinelli, Giovanni ^a   Baccarani, Michele ^a   Manzoli, Lucia ^a   Martelli, Alberto M ^a   Cocco, Lucio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE BETA 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE DELETION; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHOLIPASE C BETA; PHOSPHOLIPASE C GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 60149098150     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.3748     Document Type: Article

References (48)

1. Itzykson R, Gardin C, Fenaux P: Meeting report: Myelodysplastic syndromes at ASH 2007. Leukemia 22:893-897, 2008
2. Pfeilstocker M, Karlic H, Nosslinger T, et al: Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications. Leuk Lymphoma 48:1900-1909, 2007
3. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
4. Malcovati L, Della Porta MG, Cazzola M: Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91: 1588-1590, 2006
5. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in my- elodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007
6. Nimer SD: Myelodysplastic syndromes. Blood 111:4841-4851, 2008
7. Jabbour E, Kantarjian HM, Koller C, et al: Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112:1089-1095, 2008
8. Kelaidi C, Park S, Brechignac S, et al: Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era: The GFM experience with EPO and thalidomide. Leuk Res 32:1049-1053, 2008
9. Wymann MP, Schneiter R: Lipid signalling in disease. Nat Rev Mol Cell Biol 9:162-176, 2008
10. Ye K, Ahn JY: Nuclear phosphoinositide signaling. Front Biosci 13:540-548, 2008
11. Faenza I, Bregoli L, Ramazzotti G, et al: Nuclear phospholipase C beta1 and cellular differentiation. Front Biosci 13:2452-2463, 2008
12. Martelli AM, Gilmour RS, Bertagnolo V, et al: Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. Nature 358:242-245, 1992
13. Irvine RF: Nuclear lipid signalling. Nat RevMol Cell Biol 4:349-360, 2003
14. Manzoli L, Martelli AM, Billi AM, et al: Nuclear phospholipase C: Involvement in signal transduc-tion. Prog Lipid Res 44:185-206, 2005
15. Bristol A, Hall SM, Kriz RW, et al: Phospho-lipase C-148: Chromosomal location and deletion mapping of functional domains. Cold Spring Harb Symp Quant Biol 53:915-920, 1988
16. Peruzzi D, Calabrese G, Faenza I, et al: Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase C be- ta(1). Biochim Biochim Biophys Acta 1484:175-182, 2000
17. Choi JH, Ryu SH, Suh PG: On/off-regulation of phospholipase C-gamma 1-mediated signal trans- duction. Adv Enzyme Regul 47:104-116, 2007
18. Klein C, Malviya AN: Mechanism of nuclear calcium signaling by inositol 1,4,5-trisphosphate produced in the nucleus, nuclear located protein kinase C and cyclic AMP-dependent protein kinase. Front Biosci 13:1206-1226, 2008
19. Ferguson BJ, DoveyCL, LilleyK, etal: Nuclear phospholipase C gamma: Punctate distribution and association with the promyelocytic leukemia protein. J Proteome Res 6:2027-2032, 2007
20. Shirane M, Sawa H, Kobayashi Y, et al: Deficiency of phospholipase C-gamma1 impairs renal development and hematopoiesis. Development 128:5173-5180, 2001
21. di Giacomo V, Matteucci A, Stellacci E, et al: Expression of signal transduction proteins during the differentiation of primary human erythroblasts. J Cell Physiol 202:831-838, 2005
22. Fiume R, Faenza I, Matteucci A, et al: Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells. J Biol Chem 280:24221-24226, 2005
23. Faenza I, Matteucci A, Manzoli L, et al: A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem 275:30520-30524, 2000
24. Faenza I, Ramazzotti G, Bavelloni A, et al: Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. Endocrinology 148:1108-1117, 2007
25. Lo Vasco VR, Calabrese G, Manzoli L, et al: Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18:1122-1126,2004
26. Follo MY, Bosi C, Finelli C, et al: Real-time PCR as a tool for quantitative analysis of PI- PLCbeta1 gene expression in myelodysplastic syndrome. Int J Mol Med 18:267-271, 2006
27. Nyakern M, Tazzari PL, Finelli C, et al: Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 20:230-238, 2006
28. Follo MY, Mongiorgi S, Bosi C, et al: The Akt/mammalian target of rapamycin signal transduc- tion pathway is activated in high-risk myelodysplas- tic syndromes and influences cell survival and proliferation. Cancer Res 67:4287-4294, 2007
29. Follo MY, Finelli C, Bosi C, et al: PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 22:198-200, 2008
30. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplas-tic syndromes. Br J Haematol 51:189-199, 1982
31. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302,2002
32. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006
33. De Luca A, Bottillo I, Dasdia MC, et al: Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification. J Med Genet 44:800-808, 2007
34. Bediaga NG, Alfonso-Sanchez MA, de Renobales M, et al: GSTT1 and GSTM1 gene copy number analysis in paraffin-embedded tissue using quantitative real-time PCR. Anal Biochem 378:221-223, 2008
35. Bodin L, Beaune PH, Loriot MA: Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J Biomed Biotechnol 2005:248-253, 2005
36. Atallah E, Garcia-Manero G: Treatment strategies in myelodysplastic syndromes. Cancer Invest 26:208-216, 2008
37. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582, 2008
38. Bernasconi P, Boni M, Cavigliano PM, et al: Clinical relevance of cytogenetics in myelodys- plastic syndromes. Ann N Y Acad Sci 1089:395-410, 2006
39. Haase D: Cytogenetic features in myelodys- plastic syndromes. Ann Hematol 87:515-526, 2008
40. Slovak ML, Dewald GW: International Working Group on MDS cytogenetics: October 2007 meeting report. Leuk Res 32:1329-1332, 2008
41. Bernasconi P, Cavigliano PM, Boni M, et al: Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 17:2107-2112, 2003
42. Gohring G, Karow A, Steinemann D, et al: Chromosomal aberrations in congenital bone marrow failure disorders-an early indicator for leukemo- genesis? Ann Hematol 86:733-739, 2007
43. Mohamedali A, Gaken J, Twine NA, et al: Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110:3365-3373, 2007
44. Gondek LP, Tiu R, O'Keefe CL, et al: Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534-1542, 2008
45. Maciejewski JP, Mufti GJ: Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 112:965-974, 2008
46. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93, 2008
47. Coooo L, Faenza I, Follo MY, et al: Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes. Adv Enzyme Regul 48:2-9, 2008
48. Cocco L, Follo MY, Faenza I, et al: Nuclear inositide signaling: An appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells. Adv Enzyme Regul 47:2-9, 2007